Novel Role of CETP in Macrophages: Reduction of Mitochondrial Oxidants Production and Modulation of Cell Immune-Metabolic Profile
Carregando...
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
DORIGHELLO, Gabriel G.
ASSIS, Leandro H. P.
RENTZ, Thiago
MORARI, Joseane
RIDGWAY, Neale D.
VERCESI, Anibal E.
OLIVEIRA, Helena C. F.
Citação
ANTIOXIDANTS, v.11, n.9, article ID 1734, 17p, 2022
Resumo
Plasma cholesteryl ester transfer protein (CETP) activity diminishes HDL-cholesterol levels and thus may increase atherosclerosis risk. Experimental evidence suggests CETP may also exhibit anti-inflammatory properties, but local tissue-specific functions of CETP have not yet been clarified. Since oxidative stress and inflammation are major features of atherogenesis, we investigated whether CETP modulates macrophage oxidant production, inflammatory and metabolic profiles. Comparing macrophages from CETP-expressing transgenic mice and non-expressing littermates, we observed that CETP expression reduced mitochondrial superoxide anion production and H2O2 release, increased maximal mitochondrial respiration rates, and induced elongation of the mitochondrial network and expression of fusion-related genes (mitofusin-2 and OPA1). The expression of pro-inflammatory genes and phagocytic activity were diminished in CETP-expressing macrophages. In addition, CETP-expressing macrophages had less unesterified cholesterol under basal conditions and after exposure to oxidized LDL, as well as increased HDL-mediated cholesterol efflux. CETP knockdown in human THP1 cells increased unesterified cholesterol and abolished the effects on mitofusin-2 and TNF alpha. In summary, the expression of CETP in macrophages modulates mitochondrial structure and function to promote an intracellular antioxidant state and oxidative metabolism, attenuation of pro-inflammatory gene expression, reduced cholesterol accumulation, and phagocytosis. These localized functions of CETP may be relevant for the prevention of atherosclerosis and other inflammatory diseases.
Palavras-chave
CETP, macrophage, mitochondria, oxidants, inflammation, cholesterol
Referências
- Assis LHD, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.839428
- Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628
- Cappel DA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136915
- Cazita PM, 2008, SHOCK, V30, P590, DOI 10.1097/SHK.0b013e31816e30fd
- CHAJEK T, 1978, P NATL ACAD SCI USA, V75, P3445, DOI 10.1073/pnas.75.7.3445
- Chinetti-Gbaguidi G, 2015, NAT REV CARDIOL, V12, P10, DOI 10.1038/nrcardio.2014.173
- Collet X, 1999, J LIPID RES, V40, P1185
- Connolly NMC, 2018, CELL DEATH DIFFER, V25, P542, DOI 10.1038/s41418-017-0020-4
- de Lima C, 2008, EUR J APPL PHYSIOL, V104, P957, DOI 10.1007/s00421-008-0849-9
- Emre Y, 2010, FEBS LETT, V584, P1437, DOI 10.1016/j.febslet.2010.03.014
- Erdman LK, 2009, J IMMUNOL, V183, P6452, DOI 10.4049/jimmunol.0901374
- Flynn JM, 2011, FREE RADICAL BIO MED, V50, P866, DOI 10.1016/j.freeradbiomed.2010.12.030
- Francone OL, 1996, J LIPID RES, V37, P1268
- Grion CMC, 2010, EUR J CLIN INVEST, V40, P330, DOI 10.1111/j.1365-2362.2010.02269.x
- HPS3 TIMI55-REVEAl Collaborative, 2017, NEW ENGL J MED, V377, P1217, DOI 10.1056/NEJMoa1706444
- Ichinohe T, 2013, P NATL ACAD SCI USA, V110, P17963, DOI 10.1073/pnas.1312571110
- Ishigami M, 1997, EUR J CLIN INVEST, V27, P285, DOI 10.1046/j.1365-2362.1997.1040657.x
- Jezek J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010013
- Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793
- Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004
- Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
- Lozhkin A, 2017, J MOL CELL CARDIOL, V102, P10, DOI 10.1016/j.yjmcc.2016.12.004
- Martinon F, 2010, EUR J IMMUNOL, V40, P616, DOI 10.1002/eji.200940168
- Matsuura F, 2006, J CLIN INVEST, V116, P1435, DOI 10.1172/JCI27602
- Mills EL, 2017, NAT IMMUNOL, V18, P488, DOI 10.1038/ni.3704
- Morehouse LA, 2007, J LIPID RES, V48, P1263, DOI 10.1194/jlr.M600332-JLR200
- Oliveira HCF, 2020, ADV EXP MED BIOL, V1276, P15, DOI 10.1007/978-981-15-6082-8_2
- Oliveira HCF, 2020, MOL ASPECTS MED, V71, DOI 10.1016/j.mam.2019.100840
- Pavlou S, 2017, J INFLAMM-LOND, V14, DOI 10.1186/s12950-017-0151-x
- Quintao ECR, 2010, ATHEROSCLEROSIS, V209, P1, DOI 10.1016/j.atherosclerosis.2009.08.002
- Robinet P, 2010, J LIPID RES, V51, P3364, DOI 10.1194/jlr.D007336
- Rousset S, 2006, CYTOKINE, V35, P135, DOI 10.1016/j.cyto.2006.07.012
- Santana KG, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.684076
- Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]
- Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
- Sun Y, 2009, CIRC RES, V104, P455, DOI 10.1161/CIRCRESAHA.108.182568
- Trudeau K, 2011, INVEST OPHTH VIS SCI, V52, P8657, DOI 10.1167/iovs.11-7934
- Tschopp J, 2011, EUR J IMMUNOL, V41, P1196, DOI 10.1002/eji.201141436
- Van den Bossche J, 2017, TRENDS IMMUNOL, V38, P395, DOI 10.1016/j.it.2017.03.001
- Venancio TM, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/1784014
- Villard EF, 2012, ARTERIOSCL THROM VAS, V32, P2341, DOI 10.1161/ATVBAHA.112.252841
- Viola A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01462
- Wang Y, 2017, ARTERIOSCL THROM VAS, V37, pE99, DOI 10.1161/ATVBAHA.117.309580
- West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975
- Yvan-Charvet L, 2008, CIRCULATION, V118, P1837, DOI 10.1161/CIRCULATIONAHA.108.793869
- Zhu X, 2008, J BIOL CHEM, V283, P22930, DOI 10.1074/jbc.M801408200